Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5159725 | 0.86 | HRH3 (0.70) | HRH3HRH1 | |
| SCHEMBL3100832 | 0.84 | HRH3 (0.77) | HRH3HRH1 | |
| SCHEMBL14372309 | 0.83 | HRH3 (0.49) | HRH3HRH1 | |
| SCHEMBL3086195 | 0.82 | HRH3 (1.00) | HRH3HRH1 | |
| SCHEMBL14372310 | 0.77 | HRH3 (0.64) | HRH3HRH1 | |
| SCHEMBL5161715 | 0.77 | HRH3 (0.61) | HRH3HRH1 | |
| SCHEMBL3089910 | 0.72 | HRH3 (0.69) | HRH3HRH1 | |
| SCHEMBL5171095 | 0.72 | HRH3 (0.55) | HRH3HRH1 | |
| SCHEMBL5159251 | 0.71 | HRH3 (1.00) | HRH3HRH1 | |
| SCHEMBL5159349 | 0.71 | HRH3 (0.75) | HRH3HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232590-A1 | 3-Cylcoalkylbenzazepines as Histamine H3 Antagonists | GLAXO GROUP LIMITED (GB) | 2007-10-04 | — | — | US | claimed |
| EP-1756094-A1 | 3-CYCLOALKYLBENZAZEPINES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-02-28 | — | — | EP | claimed |
| WO-2005123723-A1 | 3-CYCLOALKYLBENZAZEPINES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-12-29 | — | — | WO | claimed |
| US-20070232590-A1 | 3-Cylcoalkylbenzazepines as Histamine H3 Antagonists | GLAXO GROUP LIMITED (GB) | 2007-10-04 | — | — | US | disclosed |
| US-20070232590-A1 | 3-Cylcoalkylbenzazepines as Histamine H3 Antagonists | GLAXO GROUP LIMITED (GB) | 2007-10-04 | — | — | US | disclosed |
| US-20070232590-A1 | 3-Cylcoalkylbenzazepines as Histamine H3 Antagonists | GLAXO GROUP LIMITED (GB) | 2007-10-04 | — | — | US | disclosed |
| EP-1756094-A1 | 3-CYCLOALKYLBENZAZEPINES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005123723-A1 | 3-CYCLOALKYLBENZAZEPINES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232590-A1 | 3-Cylcoalkylbenzazepines as Histamine H3 Antagonists | HRH3, HRH4, HRH2 | HRH3 1/4885HRH1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.